UNSPSC 51333902: Terbequinil

This classification denotes an antipsychotic agent with the molecular formula C15H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DH9WUS03O, chemically known as 1,4-dihydro-1-(methoxymethyl)-4-oxo-n-propyl-3-quinolinecarboxamide but generally known as terbequinil, which bears US NIH Compound Identifier 65916. European Medicines Agency schedules Terbequinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10908MIG.

UNSPSC 51333902 Terbequinil is a Commodity code that in practice encompasses pharmaceutical procurement across state and local health agencies, though recent solicitations under this code show substantial scope drift toward naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and pharmacy benefit program management rather than terbequinil itself. State and local governments buying under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. The work being solicited ranges from direct procurement of naloxone and harm-reduction products for community health initiatives to large-scale generic pharmaceutical supply contracts and exploratory market intelligence on direct-to-manufacturer prescription programs designed to bypass traditional pharmacy benefit managers and wholesalers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a two-year term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program outside traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products with awarded contracts effective July 1, 2026, and participation from authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. The code shows material misalignment between its nominal scope and active procurement — terbequinil itself does not appear in any of the three recent opportunities.